CHMP recommends changes to Velcade and Pradaxa labels
This article was originally published in Scrip
Executive Summary
Experts on the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) have adopted positive opinions recommending variations to the terms of the marketing authorisations for Janssen's Velcade (bortezomib) and Boehringer Ingelheim's Pradaxa (dabigatran etexilate).